MX2022008046A - Compuestos para el tratamiento de mielofibrosis. - Google Patents

Compuestos para el tratamiento de mielofibrosis.

Info

Publication number
MX2022008046A
MX2022008046A MX2022008046A MX2022008046A MX2022008046A MX 2022008046 A MX2022008046 A MX 2022008046A MX 2022008046 A MX2022008046 A MX 2022008046A MX 2022008046 A MX2022008046 A MX 2022008046A MX 2022008046 A MX2022008046 A MX 2022008046A
Authority
MX
Mexico
Prior art keywords
myelofibrosis
compounds
treatment
patient
pharmaceutically acceptable
Prior art date
Application number
MX2022008046A
Other languages
English (en)
Inventor
Andrew Mazar
Francis J Giles
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of MX2022008046A publication Critical patent/MX2022008046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para tratar mielofibrosis en un paciente mediante la administración al paciente de una cantidad terapéuticamente efectiva de un inhibidor de GSK-3ß tal como 3-(5-fluorobenzofuran-3-il)-4-(5-meti l-5H-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona, o una sal farmacéuticamente aceptable de la misma, opcionalmente en combinación con una cantidad terapéuticamente efectiva de un inhibidor de JAK tal como ruxolitinib, o una sal farmacéuticamente aceptable del mismo.
MX2022008046A 2019-12-26 2020-12-23 Compuestos para el tratamiento de mielofibrosis. MX2022008046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962953654P 2019-12-26 2019-12-26
PCT/US2020/066762 WO2021133866A1 (en) 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis

Publications (1)

Publication Number Publication Date
MX2022008046A true MX2022008046A (es) 2022-11-14

Family

ID=74186982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008046A MX2022008046A (es) 2019-12-26 2020-12-23 Compuestos para el tratamiento de mielofibrosis.

Country Status (11)

Country Link
US (1) US20230062278A1 (es)
EP (1) EP4081213A1 (es)
JP (1) JP2023508491A (es)
KR (1) KR20230005808A (es)
CN (1) CN115697323A (es)
AU (1) AU2020415440A1 (es)
BR (1) BR112022012819A2 (es)
CA (1) CA3166251A1 (es)
IL (1) IL294369A (es)
MX (1) MX2022008046A (es)
WO (1) WO2021133866A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) * 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
CA3178452A1 (en) * 2012-11-15 2014-05-22 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
EP3074016A2 (en) * 2013-11-26 2016-10-05 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료
KR20210045364A (ko) * 2018-06-05 2021-04-26 액투에이트 테라퓨틱스 인크. 악성 림프증식성 장애를 치료하는 방법

Also Published As

Publication number Publication date
WO2021133866A1 (en) 2021-07-01
US20230062278A1 (en) 2023-03-02
EP4081213A1 (en) 2022-11-02
JP2023508491A (ja) 2023-03-02
BR112022012819A2 (pt) 2022-09-06
CA3166251A1 (en) 2021-07-01
AU2020415440A1 (en) 2022-08-04
KR20230005808A (ko) 2023-01-10
IL294369A (en) 2022-08-01
CN115697323A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
EA201590345A1 (ru) Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
MY155255A (en) Spiro-oxindole compounds and their use as therapeutic agents
TNSN06228A1 (en) Compounds and methods of use
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
EA201200253A1 (ru) Композиция для лечения муковисцидоза
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2022000143A (es) Metodos novedosos.
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
PH12020500666A1 (en) Pladienolide compounds and their use
TW200742580A (en) Methods for treating nephrolithiasis
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
EA202193276A1 (ru) Способы лечения холангиокарциномы
JOP20210319A1 (ar) مركبات بيروليدين
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.